Back to Report Store Home

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

  • Published: Oct-2017
  • Report Code: GBIHC456MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 10

2.1 Disease Introduction 10

2.2 Epidemiology 11

2.3 Symptoms 11

2.4 Etiology and Pathophysiology 12

2.5 Diagnosis 14

2.6 Classification 16

2.7 Prognosis 17

2.8 Treatment Options 17

2.8.1 Treatment Algorithm 18

2.8.2 Non-insulin T2DM Therapies 20

2.8.3 Insulin T2DM Therapies 23

2.9 Treatment Segments 25

2.9.1 Non-Insulin Therapies 25

2.9.2 Insulin Therapies 41

2.10 Co-morbidities and Complications 44

2.11 Non-pharmacological Treatments 46

2.11.1 Dietary Interventions 46

2.11.2 Exercise 46

3 Marketed Products 47

3.1 Overview 47

3.2 Biguanides 48

3.2.1 Metformin 48

3.3 Sulfonylureas 49

3.4 Thiazolidinediones 51

3.4.1 Pioglitazone 51

3.4.2 Duvie (lobeglitazone) – Chong Kun Dang 52

3.5 GLP-1 Receptor Agonists 52

3.5.1 Byetta (exenatide) – AstraZeneca 52

3.5.2 Bydureon (exenatide) – AstraZeneca 53

3.5.3 Victoza (liraglutide) – Novo Nordisk 55

3.5.4 Lyxumia (lixisenatide) – Sanofi 56

3.5.5 Tanzeum (albiglutide) – GlaxoSmithKline 58

3.5.6 Trulicity (dulaglutide) – Eli Lilly 59

3.6 DPP-4 Inhibitors 60

3.6.1 Januvia (sitagliptin) – Merck & Co. 60

3.6.2 Galvus (vildagliptin) – Novartis 62

3.6.3 Onglyza (saxagliptin) – Bristol-Myers Squibb/AstraZeneca 63

3.6.4 Tradjenta (linagliptin) – Bristol-Myers Squibb/AstraZeneca 64

3.6.5 Zemiglo (gemigliptin) – LG Life Sciences 65

3.6.6 Suganon (evogliptin) – Dong-A ST 66

3.6.7 Gadret (anagliptin) – JW Pharmaceutical 67

3.6.8 Nesina (alogliptin) – Takeda 67

3.6.9 Tenelia (teneligliptin) – Mitsubishi Tanabe Pharma 68

3.7 SGLT-2 Inhibitors 69

3.7.1 Forxiga (dapagliflozin) – AstraZeneca 69

3.7.2 Invokana (canagliflozin) – Janssen 71

3.7.3 Jardiance (empagliflozin) – Boehringer Ingelheim 72

3.7.4 Suglat (ipragliflozin) – Astellas 73

3.8 Insulin Therapies 74

3.8.1 Lantus (insulin glargine) – Sanofi 74

3.8.2 Levemir (insulin detemir) – Novo Nordisk 75

3.8.3 Tresiba (insulin degludec) – Novo Nordisk 76

3.8.4 Toujeo (insulin glargine) – Sanofi 77

3.9 Comparative Efficacy and Safety of Marketed Products 78

4 Pipeline Analysis 84

4.1 Overview 84

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 85

4.3 Pipeline by Molecular Target 87

4.4 Promising Pipeline Molecules 91

4.4.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide) – Novo Nordisk 91

4.4.2 Ertugliflozin – Pfizer 95

4.4.3 Bexagliflozin – Theracos 96

4.4.4 Omarigliptin – Merck & Co. 97

4.4.5 Sotagliflozin– Sanofi 99

4.5 Comparative Efficacy and Safety of Pipeline Products 101

4.6 Product Competitive Framework 102

5 Clinical Trial Analysis 105

5.1 Failure Rate 105

5.1.1 Overall Failure Rate 105

5.1.2 Failure Rate by Phase and Molecule Type 107

5.1.3 Failure Rate by Phase and Molecular Target 107

5.2 Clinical Trial Duration 108

5.2.1 Trial Duration by Molecule Type and Stage of Development 108

5.2.2 Trial Duration by Molecular Target and Stage of Development 109

5.3 Clinical Trial Size 110

5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 110

5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 113

5.4 Summary of Clinical Trial Metrics 114

6 Multi-Scenario Forecast 116

6.1 Geographical Markets 116

6.2 South-East Asia Markets 116

6.3 South Korea 119

6.3.1 Treatment Usage Patterns 119

6.3.2 Annual Cost of Therapy 120

6.3.3 Market Size 120

6.4 Singapore 121

6.4.1 Treatment Usage Patterns 121

6.4.2 Annual Cost of Therapy 122

6.4.3 Market Size 123

6.5 Taiwan 123

6.5.1 Treatment Usage Patterns 123

6.5.2 Annual Cost of Therapy 124

6.5.3 Market Size 125

6.6 Malaysia 125

6.6.1 Treatment Usage Patterns 125

6.6.2 Annual Cost of Therapy 126

6.6.3 Market Size 127

6.7 Philippines 127

6.7.1 Treatment Usage Patterns 127

6.7.2 Annual Cost of Therapy 128

6.7.3 Market Size 129

6.8 Thailand 130

6.8.1 Treatment Usage Patterns 130

6.8.2 Annual Cost of Therapy 131

6.8.3 Market Size 132

6.9 Vietnam 132

6.9.1 Treatment Usage Patterns 132

6.9.2 Annual Cost of Therapy 133

6.9.3 Market Size 134

6.10 Indonesia 135

6.10.1 Treatment Usage Patterns 135

6.10.2 Annual Cost of Therapy 136

6.10.3 Market Size 137

7 Drivers and Barriers 138

7.1 Drivers 138

7.1.1 Aging Population, Increasing Obesity and Growing Economy 138

7.1.2 Increasing Awareness of T2DM 138

7.1.3 Continued Uptake of Recently Approved Drug Classes 138

7.1.4 Promising Late-Stage Pipeline Products Can Change the Treatment Paradigm 138

7.1.5 Enhanced Usage of Combination Therapies 139

7.2 Barriers 139

7.2.1 Non-pharmacological First-line Treatment 139

7.2.2 Widespread Usage of Generic Drugs 139

7.2.3 Poor Adherence to Treatment Regimens 139

7.2.4 Generic Erosion Resulting from Patent Expirations 139

8 Deals and Strategic Consolidations 140

8.1 Licensing Deals 140

8.1.1 Deals by Region and Value 140

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 141

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 142

8.1.4 Key Licensing Deals 145

8.2 Co-development Deals 148

8.2.1 Deals by Region and Value 148

8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 149

8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 151

8.2.4 Key Co-development Deals 153

9 Appendix 157

9.1 All Pipeline Drugs by Stage of Development 157

9.1.1 Discovery 157

9.1.2 Preclinical 161

9.1.3 IND/CTA-filed 172

9.1.4 Phase I 173

9.1.5 Phase II 175

9.1.6 Phase III 178

9.1.7 Pre-registration 179

9.2 Summary of Multi-Scenario Market Forecasts to 2023 179

9.2.1 South-East Asia 179

9.2.2 South Korea 180

9.2.3 Singapore 180

9.2.4 Taiwan 181

9.2.5 Malaysia 181

9.2.6 Philippines 182

9.2.7 Thailand 182

9.2.8 Vietnam 183

9.2.9 Indonesia 183

9.3 Bibliography 184

9.4 Abbreviations 196

9.5 Research Methodology 198

9.5.1 Secondary Research 198

9.5.2 Marketed Product Profiles 199

9.5.3 Late-Stage Pipeline Candidates 199

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 199

9.5.5 Product Competitiveness Framework 199

9.5.6 Pipeline Analysis 200

9.5.7 Forecasting Model 201

9.5.8 Deals Data Analysis 201

9.6 Contact Us 202

9.7 Disclaimer 202

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards